Krazati (Adagrasib)

Adagrasib covalently binds to the cysteine residue of the KRAS G12C mutant protein, locking it in an inactive GDP‑bound state. This prevents activation of the MAPK signaling pathway, which is essential for cancer cell proliferation and survival, thereby inhibiting tumor growth.

The dosage of Krazati is individualized and determined by the prescribing oncologist based on the patient’s clinical condition, renal and hepatic function, and other relevant factors. Specific dosing regimens are not disclosed publicly and should follow the prescriber’s instructions.

Safety data for adagrasib in pregnant or lactating women are limited. The product should be avoided during pregnancy and breastfeeding unless the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician.

To order Krazati, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

The primary alternative KRAS G12C inhibitor is sotorasib (Lumakras). Both agents target the same mutation but differ in chemical structure, dosing schedule, and safety profile. Clinical data suggest comparable efficacy, while side‑effect patterns vary; for example, sotorasib may have a higher incidence of liver enzyme elevations, whereas adagrasib shows more gastrointestinal events.

Krazati should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Krazati is supplied as an oral tablet that should be swallowed whole with water. It is taken once daily, preferably at the same time each day, and can be taken with or without food unless otherwise directed by the prescriber.

Serious risks include significant liver enzyme elevations, interstitial lung disease or pneumonitis, cardiac arrhythmias, severe skin reactions such as Stevens‑Johnson syndrome, and rare thromboembolic events. Patients should report any new respiratory symptoms, chest pain, jaundice, or severe skin changes to their healthcare provider promptly.

Krazati should not be used by individuals with known hypersensitivity to adagrasib or any of the tablet excipients. It is also contraindicated in patients with severe hepatic impairment and should be used with caution in those with moderate liver dysfunction. Pregnant or breastfeeding women should avoid it unless absolutely necessary.